Myriad Genetics (MYGN) 2026 Stephens Annual Investment Conference | NASH2026 summary
Event summary combining transcript, slides, and related documents.
2026 Stephens Annual Investment Conference | NASH2026 summary
18 Nov, 2026Q3 performance and portfolio changes
Prenatal assets sold to LabCorp for $210M cash; transaction expected to close in H1 2027, likely earlier in the half, with 500 employees transitioning.
Sale expected to lift revenue growth by >100 bps and gross margin by >500 bps; about one-third of transferring employees support lab operations and COGS.
Q3 revenue improved $10M-$12M, with the increase flowing through to adjusted EBITDA; Q2's $11M change-in-estimate/out-of-period revenue impact was immaterial in Q3.
Prenatal transition costs and OpEx efficiencies will phase in through 2027; Ascend is a multi-period effort spanning six revenue and cost value streams.
Ascend benefits are expected in 2027, with further impact as capabilities scale into 2028.
Hereditary cancer growth and execution
Management cited a $2B affected market and $5B unaffected market, with further penetration opportunity in both; rising cancer incidence and stronger guidelines support market growth.
NCCN guideline effects are expected to flow gradually into physician practice and payer policies, supporting a market tailwind rather than a specific quarterly volume step-up.
Q3 RCM execution improved after Q2 friction; priorities include adapting to prior-authorization changes, automating medical-record retrieval and strengthening payer relationships.
2027 priorities include improving physician experience and RCM execution to support hereditary cancer volumes and revenue.
Precise MRD roadmap
Breast MolDX submission was made in mid-July; approval is expected in H1 2027, probably late in the half, based on a 9-12 month review timeline.
CRC and renal submissions are planned over the next several months; endometrial and ovarian submissions are expected in late 2027.
MRD volume will be metered in 2027, with more significant ramping as multiple indications gain approval and reimbursement broadens.
More than a dozen clinical trials are underway; Precise MRD clinical costs are expected to rise in 2027 vs. 2026, with a specialty sales team supporting broader oncology sales.
Latest events from Myriad Genetics
- Cancer-focused investment, operational resets and cautious guidance define the recovery plan.MYGN
UBS Global Healthcare Conference - Higher guidance and a planned $210M Prenatal Health sale follow sequential Q3 gains.MYGN
Q3 2026 - Revenue and ASPs declined, but strategic focus on cancer care and operational initiatives aim to drive recovery.MYGN
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 revenue dropped 11% year-over-year, leading to lower guidance and efficiency actions.MYGN
Q2 2026 - All proposals passed, directors elected, and no stockholder questions were raised.MYGN
AGM 2026 - Q1 2026 revenue rose 2% to $200.4M, with strong cancer and mental health growth; guidance reaffirmed.MYGN
Q1 2026 - Q3 2024 revenue up 11%, but GeneSight faces major payor risk in 2025.MYGN
Q3 2024 - Q1 2025 revenue fell 3% year-over-year; 2025 guidance lowered amid GeneSight and hereditary cancer headwinds.MYGN
Q1 2025 - 2024 revenue up 11% to $838M, with strong segment growth and reaffirmed 2025 guidance.MYGN
Q4 2024